A Phase I Trial of Standard and Cyclophosphamide Dose-Escalated CHOP with Granulocyte Colony Stimulating Factor in Elderly Patients with Non-Hodgkin's Lymphoma

References

• International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Hoskens P.J., Ng V., Spinelli J.J., Klimo P., Connors J.M. Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B. J Clin Oncol 1991; 9: 220–226
   PubMed Web of Science ®Google Scholar
• Coiffier B., Gisselbrecht C., Vose J.M., Tilly H., Herbrecht R., Bosly A., Armitage J.O. Prognostic factors in aggressive malignant lymphoma and validation of a prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 1991; 9: 211–219
   PubMed Web of Science ®Google Scholar
• Vose J.M., Armitage J.O., Weisenburger D.D., Bierman P.J., Sorensen S., Hutchins M., Moravee D.F., Howe D., Dowling M.D., Maillard J., Johnson P.S., Pevnick W., Packard W.M., Okerbloom J., Thompson R.F., Langdon R.M., Soori G., Peterson C. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1988; 6: 1838–1844
   PubMed Web of Science ®Google Scholar
• Armitage J.O., Potter J.F. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly. J Am Geriatr Soc 1984; 32: 269–273
   PubMed Web of Science ®Google Scholar
• Balducci L., Parker M., Sexton W., Tantranond P. Pharmacology of antineoplastic agents in the elderly patient. Semin Oncol 1989; 16: 76–84
   PubMed Web of Science ®Google Scholar
• McMaster M.L., Johnson D.H., Greer J.P., Wolff S.N., Hildreth C.R., Greco A., Hainsworth. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma. Cancer 1991; 67: 1487–1492
   PubMed Web of Science ®Google Scholar
• Tirelli U., Zagonel V., Serraino S.R., Talamini R., De Cicco M., Carbone A., Monfardini S. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma. J Clin Oncol 1992; 10: 228–236
   PubMed Web of Science ®Google Scholar
• O'Reilly S.E., Connors J.M., Howdle S., Hoskins P., Klasa R., Klimo P., Stuart DS. In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: Results of a phase II study of P/DOCE chemotherapy. J Clin Oncol 1993; 11: 2250–2257
   PubMed Web of Science ®Google Scholar
• Martelli M., Guglielmi C, Coluzzi S., Avvisati G., Amadori S., Giovannini M., Torromeo C., Mandelli F.P. VAPEC: A prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 2362–2369
   PubMed Web of Science ®Google Scholar
• Meyer R.M., Browman G.P., Samosh M.L., Benger A.M., Bryant-Lukosius D., Wilsom W. E.C, Frank G.L., Laber B.F., Sternbach M.S., Foster G.A., Skingley P., Levine M.N. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 2386–2393
   PubMed Web of Science ®Google Scholar
• Sonneveld P., de Ridder M., van der Lelie H., Nieuwenhuis K., Schouten H., Mulder A., van Reijswoud I., Hop W., Lowenberg B. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995; 13: 2530–2539
   PubMed Web of Science ®Google Scholar
• Tirelli U., Van Glabbeke M., Teodorovic I., Thomas J., Bron D., Kluin-Nelemans J.C, Somers R., Rosti G., Roozendaal ZagonelV., Monfardini S., Noordijk E.M. A randomized comparison of CHOP vs. a new combination of VP-16, mitoxantrone and prednimustine (VMP) in patients >70 years of age with intermediate-high grade NHL. Proc Am Soc Clin Oncol 1995; 14: 398, abstr
   Google Scholar
• McKelvey E.M., Gottlieb J.A., Wilson H.E., Haut A., Talley R.W., Stephens R., Lane M., Gamble J.F., Jones S.E., Grozea P.N., Gutterman J., Coltman C., Moon T.E. Hydroxyldaunorubicin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484–1493
   PubMed Web of Science ®Google Scholar
• Coiffier B., Biron P., Bastion Y., Haioun C, Bordessoulle D., Sebban C, Blanc M., Tilly H., Salles B., Bouabdallah R., Gisselbrecht C. Elderly lymphoma patients have a long survival if treated with a curative intent. A study from the G.E.L.A. on 453 patients older than 69 years. Proc ASCO 1996; 15: 417, abstr
   Google Scholar
• Pettengell R., Gurney H., Radford J.A., Deakin D.A., James R., Wilkinson P.M., Kane K., Bentley J., Crowther D. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 1992; 80: 1430–1436
   PubMed Web of Science ®Google Scholar
• Crawford J., Ozer H., Stoller R., Johnson D., LymanTabbara I., Kris M., Grous J., PicozziRausch G., Smith R., Gradishar W., Yahanda A., Vincent M., Stewart M., Glaspy J. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164–170
   PubMed Web of Science ®Google Scholar
• The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Carbone P.P., Kaplan H.S., Musshoff K., Smithers D.W., Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Oken M.M., Creech R.H., Tormey D.C, Horton J., Davis T.E., McFadden E.T., Carbone P.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655
   PubMed Web of Science ®Google Scholar
• Miller A.B., Hogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214
   PubMed Web of Science ®Google Scholar
• Hryniuk W.M. The importance of dose intensity in the outcome of chemotherapy. Advances in Oncology, S. Hellman, V. DeVita, S. Rosenberg. J.B. Lippincott Co., Philadelphia, Pa 1988; 121–141
   Google Scholar
• Mood A., Graybill F., Boes D. Introduction to the Theory of Statistics, 3rd ed. McGraw-Hill Book Company. 1963
   Google Scholar
• Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. Amer. Stat. Assoc. J. 1958; 53: 457–481
   Web of Science ®Google Scholar
• Meyer R.M., Quirt I.C, Skillings J.R., Cripps M.C, Bramwell V. H.C, Weinerman B.H., Gospodarowicz M.K., Burns B.F., Sargeant A.M., Shepherd L.E., Zee B., Hryniuk W.M. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 1770–1776
   PubMed Web of Science ®Google Scholar
• Gaynor E.R., Dahlberg S., Fisher R.I. Factors affecting reduced survival of the elderly with intermediate and high grade lymphoma: an analysis of SWOG-8516 (INT 0067): The national high priority lymphoma study-A randomized comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B. Proc ASCO 1994; 13: 370, abstr
   Google Scholar